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Background: Identification of novel molecular biomarkers will improve the management of patients with gastric
cancer (GC). Prenyl diphosphate synthase subunit 2 (PDSS2) is required for coenzyme Q10 biosynthesis and acts as
a tumor suppressor; however, the role and regulatory mechanisms of PDSS2 in GC are not understood. The aim of
this study was to determine expression status and regulatory mechanisms of PDSS2 in GC.
Methods: Associations between expression and methylation of PDSS2 were evaluated using GC cell lines. The
clinical significance of PDSS2 expression was evaluated using 238 pairs of surgically resected gastric tissues with
subgroup analysis based on GC subtypes.
Results: The expression of PDSS2 mRNA was decreased in 73% of GC cell lines compared with the control
non-cancerous cell. The PDSS2 promoter was hypermethylated in cells with decreased PDSS2 expression, and
treating these cells with a methylation inhibitor reactivated PDSS2 expression. GC tissues expressed significantly
lower mean levels of PDSS2 mRNA compared with adjacent normal tissues (P <0.001). The expression pattern of
PDSS2 protein was consistent with that of its mRNA. The decrease of PDSS2 mRNA expression in GC tissues (less
than half the level of expression detected in the corresponding normal adjacent tissues) correlated significantly
with elevated levels of carbohydrate antigen 19-9 (P = 0.015), lymph node metastasis (P = 0.022), and shorter
recurrence-free survival after curative resection (P = 0.022). Further, multivariate analysis identified PDSS2 mRNA
expression as an independent prognostic factor (hazard ratio 1.95, 95% confidence interval 1.22–3.09, P = 0.005),
and its expression pattern and prognostic significance were similar among three GC subtypes.
Conclusions: PDSS2 encodes a putative tumor suppressor, and we show here that its expression was regulated
by hypermethylation of its promoter in GC cells. Inhibition of PDSS2 mRNA expression may serve as a novel
biomarker of all types of GC.
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Although the incidence of gastric cancer (GC) is declining
in most developed countries, it remains one of the most
common causes of cancer-related death worldwide [1-3].
Appropriate stratification of patients is a pivotal aspect
of individualized treatment, leading to reducing mortality
from this cancer [4,5].* Correspondence: m-kanda@med.nagoya-u.ac.jp
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unless otherwise stated.According to its epidemiology, pathology, and location
in the body, GC is recognized as three distinct malignancies
arising in the same organ [6-8]. Shah et al. [9] proposed a
convincing classification of GC according to histopatho-
logic and anatomic criteria as follows: (1) proximal nondif-
fuse GC where the tumor is located mainly in the gastric
cardia with evidence of precursor glandular dysplasia or in
situ carcinoma in the presence of chronic inflammation,
usually without atrophy; (2) diffuse GC, which may be
located anywhere in the stomach with no apparenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of cells with a poorly differentiated phenotype; and (3)
distal nondiffuse GC, which is located mainly in the distal
stomach with evidence of chronic gastritis that is predom-
inantly differentiated or exhibits an intestinal phenotype.
In this study, they demonstrated that the three GC sub-
types are distinguished by their gene expression profiles.
Therefore, the genetic diversity of GC subtypes should be
considered in studies of genetic and epigenetic alterations
related to gastric carcinogenesis and progression.
Prenyl diphosphate synthase subunit 2 (PDSS2) was
identified in 2005 [10], and evidence indicates that it acts
as a tumor suppressor [11,12]. PDSS2 is required for the
synthesis of coenzyme Q10 (CoQ10) [13,14], which is
synthesized in the mitochondrial inner membrane and
plays a vital role in the mitochondrial respiratory chain,
pyrimidine nucleoside biosynthesis, and modulation of
apoptosis [15]. PDSS2 resides within the chromosomal
locus 6q16.3-21, a site of frequent microsatellite DNA
instability and loss of heterozygosity (LOH) in GC [16,17],
supporting its role as a tumor suppressor in gastric epithe-
lial cells. Moreover, PDSS2 may suppress the development
of malignant melanomas and lung cancers [11,12]. More-
over, Chen et al. reported that enforced overexpression of
PDSS2 leads to apoptosis in a GC cell line by causing cell
cycle arrest in the G0/G1 phase [18]. These reports led us
to make a hypothesis that PDSS2 is a potential GC-related
gene and a candidate of novel clinically-relevant prognos-
tic marker of GC.
In this study, expression and methylation status of PDSS2
in GC were determined to evaluate the clinical significance
and regulatory mechanisms of PDSS2 expression in GC.
Our results indicate that PDSS2 expression provides a




This study conformed to the ethical guidelines of the
World Medical Association Declaration of Helsinki‐Ethical
Principles for Medical Research Involving Human Subjects
and has been approved by the Institutional Review Board of
Nagoya University, Japan. Written informed consent for
usage of clinical samples and data, as required by the insti-
tutional review board, was obtained from all patients [4].
Sample collection
Eleven GC cell lines (H111, KATOIII, MKN1, MKN28,
MKN45, MKN74, NUGC2, NUGC3, NUGC4, SC-2-NU
and SC-6-LCK) and CCL-241 (non-cancerous cell line
derived from the small intestine) were obtained from the
American Type Culture Collection (Manassas, VA, USA)
or Tohoku University, Japan. The GC cell lines were cul-
tured at 37°C in RPMI-1640 (Sigma-Aldrich, St. Louis,MO, USA) supplemented with 10% fetal bovine serum
in an atmosphere containing 5% CO2. For CCL-241,
30 ng/ml of the epidermal growth factor (Sigma-Aldrich)
was added in the medium. Primary GC tissues and
corresponding normal adjacent tissues were collected
from 238 patients who underwent gastric resection for
GC at Nagoya University Hospital between 2001 and
2012. Patients who received neoadjuvant therapy were
excluded because it was difficult to obtain cancer cells
from scarred tissues. Specimens were classified histologi-
cally using the 7th edition of the Union for International
Cancer Control (UICC) classification [19]. Relevant clin-
icopathological parameters were acquired from medical
records. To evaluate whether the expression level of
PDSS2 correlated with tumor phenotype, patients were
categorized into three groups according to the definition
of GC subtypes according to the criteria of Shah et al.
[9] as follows: proximal nondiffuse, diffuse, and distal
nondiffuse type. Since 2006, adjuvant chemotherapy using
S-1 (an oral fluorinated pyrimidine) is administered to all
UICC stage II–III patients with GC unless contraindicated
by the patient’s condition [20]. Patients were followed at
least once every 3 months for 2 years after surgery and
then every 6 months for 5 years or until death. Physical
examination, laboratory tests, and enhanced computed
tomography (chest and abdominal cavity) were performed
at each visit. Chemotherapy for patients with distant
metastasis or after recurrence was determined by physi-
cian’s discretion.
Tissue samples were immediately frozen in liquid nitro-
gen and stored at −80°C. Tumor samples without necrotic
areas (approximately 5 mm2) were extracted by gross
observation and only samples confirmed to comprise
more than 80% tumor components by H&E staining
were included in this study. Corresponding normal
adjacent gastric mucosa samples >5 cm from the edge of
the tumors were obtained from the same patient [21].
Quantitative real-time reverse-transcription polymerase
chain reaction (qRT-PCR)
Total RNAs (10 μg per sample) were isolated from 11
GC cell lines, CCL-241, 238 primary GC tissues and
corresponding normal adjacent tissues were used to gen-
erate cDNAs, which were amplified using specific PCR
primers (Additional file 1: Table S1). Real-time detection
of SYBR® Green fluorescence intensity was conducted
using an ABI StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). The expres-
sion of GAPDH mRNA was quantified in each sample
for standardization. The qRT-PCR reactions in each
sample were performed in triplicate. The expression
level of each sample is presented as the value of the
PDSS2 amplicon divided by that of GAPDH [22]. PDSS2
mRNA expression was defined as decreased in GC tissues
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normal adjacent tissue.Analysis of the promoter region of PDSS2
The nucleotide sequence of the PDSS2 promoter region
was analyzed to determine the presence or absence of
CpG islands defined as follows: at least a 200-bp region of
DNA with a high GC content (>50%) and an Observed
CpG/Expected CpG ratio ≥0.6 [23]. We used CpG Island
Searcher software (http://cpgislands.usc.edu/) to deter-
mine the locations of CpG islands [24].Methylation-specific PCR (MSP) and bisulfite sequence
analysis
PDSS2 possesses a CpG island near its promoter region,
and we hypothesized that aberrant methylation is respon-
sible for regulating the transcription of PDSS2 in GC.
DNA samples from 11 GC cell lines treated with bisulfite
were subjected to MSP and nucleotide sequence analysis
[25]. The primer sequences used for MSP and bisulfite
sequencing are listed in Additional file 1: Table S1.5-Aza-2′-deoxycytidine (5-aza-dC) treatment
To assess the relation of promoter hypermethylation to
PDSS2 transcription, GC cells (1.5 × 106) were treated
with 5-aza-dC (Sigma-Aldrich) to inhibit DNA methyla-
tion and cultured for 6 days with medium changes on
days 1, 3, and 5. RNA was extracted, and RT-PCR was
performed as described [7].Immunohistochemistry (IHC)
IHC analysis of the localization of PDSS2 was performed
using a mouse monoclonal antibody against PDSS2
(ab119768, Abcam, Cambridge, UK) diluted 1:150 in
antibody diluent (Dako, Glostrup, Denmark) to probe 30
representative formalin-fixed and paraffin-embedded
sections of well-preserved GC tissue described previ-
ously [3]. Staining patterns were compared between GCs
and the corresponding normal adjacent tissues. To avoid
subjectivity, the specimens were randomized and coded
before analysis by two independent observers who were
unaware of the status of the samples. Each observer
evaluated all specimens at least twice to minimize intra-
observer variation [7].Evaluation of the clinical significance of PDSS2 expression
Correlations between the pattern of PDSS2 mRNA expres-
sion and clinicopathological parameters were evaluated
according to the differences among the three GC subtypes.
Subgroup analysis of survival according to GC subtype was
performed to determine the influence of PDSS2 expression
on patients’ outcomes.Statistical analysis
Relative levels of mRNA expression (PDSS2/GAPDH)
between GC and adjacent normal tissues were analyzed
using the Mann–Whitney U test. The χ2 test was used to
analyze the significance of the association between the
expression and methylation status of PDSS2 and clinico-
pathological parameters. Disease-specific and disease-free
survival rates were calculated using the Kaplan–Meier
method, and the difference in survival curves was analyzed
using the log-rank test. We performed multivariate regres-
sion analysis to detect prognostic factors using the Cox
proportional hazards model, and variables with P < 0.05
were entered into the final model. All statistical analyses
were performed using JMP 10 software (SAS Institute Inc,
Cary, NC, USA). A value of P < 0.05 was considered statis-
tically significant.
Results
Identification of a CpG island in the PDSS2 promoter
A CpG island was identified in the PDSS2 promoter
region using the CpG Island Searcher. The properties of
the CpG island are as follows: 1655 bp, 55.9% GC, and
0.70 Observed CpG/Expected CpG ratio (Figure 1A).
Therefore, we hypothesized that hypermethylation of the
CpG islands regulates the expression of PDSS2 in GC.
PDSS2 mRNA expression and methylation status in GC
cell lines
Significant decreases in PDSS2 mRNA levels were detected
in seven (73%) of 11 GC cell lines compared with the
expression level of the CCL-241 cell (Data for GC tissues
are described below). There was no apparent difference
in expression levels between cell lines derived from
differentiated and undifferentiated GCs (Figure 1B).
Hypermethylation of the PDSS2 promoter was detected
in MKN1, SC-2-NU, KATOIII, MKN45, and NUGC3 cells
(Figure 1B). To determine whether hypermethylation of
the PDSS2 promoter inhibited transcription, mRNA
expression levels were compared before and after treat-
ing cells with the methylation inhibitor 5-aza-dC. PDSS2
mRNA levels were restored in cells with down-regulated
PDSS2 expression accompanying hypermethylation after
5-aza-dC treatment (Figure 1B), indicating that promoter
hypermethylation inhibited PDSS2 transcription in GC.
Representative chromatograms of the sequence analysis of
the PDSS2 promoter region in MKN28 (complete methy-
lation) and NUGC4 (absence of methylation) cells are
shown in Figure 1C.
Patient characteristics
The patient population included 179 males and 59 females
aged from 20 to 84 years (65.3 ± 11.7 years, mean ± stand-
ard deviation). Pathologically, 139 and 99 patients were
diagnosed with undifferentiated and differentiated GC,
Figure 2 Expression analyses of PDSS2 in clinical specimens.
(A) The mean level of PDSS2 mRNA in GC tissues compared with
the corresponding normal adjacent tissues and in GC tissues
between patients with undifferentiated GC and differentiated GC.
(B) Representative IHC data comparing PDSS2 expression in tumor
and adjacent normal adjacent tissue (magnified 100× and 400×).
N, normal adjacent tissue; T, tumor tissue.
Figure 1 Methylation analyses of PDSS2 in GC cell lines. (A)
The CpG island indicated by the blue line is centered on the PDSS2
transcription initiation site extending upstream into the promoter region.
(B) Bar graphs indicate PDSS2 mRNA expression levels in CCL-241
(control non-cancerous cell) and GC cell lines before or after 5-aza-dC
treatment. The methylation status of the PDSS2 promoter was evaluated
using MSP, and the results are enclosed in the box. M, methylated;
pM, partially methylated; U, unmethylated. (C) Representative results of
bisulfite sequence analysis. All CpG sites in KATOIII cell were retained as
CG and those of MKN74 were converted to TG.
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phenotypes as follows: nondiffuse, 54; diffuse, 48; and
distal nondiffuse, 136. According to the 7th edition of
the UICC classification, 58, 40, 71 and 69 patients were
in stages I, II, III and IV, respectively. One hundred sixty-
four patients in stages I–III underwent R0 resection. Sixty
of the 69 patients in UICC stage IV were diagnosed as
stage IV due to positive peritoneal lavage cytology,
localized peritoneal metastasis or distant lymph node
metastasis. Eight of patients in stage IV had synchron-
ous liver metastasis, one had lung metastasis, and they
underwent gastrectomy aimed to control bleeding or
obstruction to the passage of food.
Expression levels of PDSS2 mRNA and protein in
surgically resected tissues
The mean expression level of PDSS2 mRNA was lower
in GC tissues compared with that of normal adjacent
tissues (P <0.001); however, there was no significantdifference in PDSS2 mRNA expression levels between pa-
tients with undifferentiated or differentiated GC (Figure 2A).
The expression pattern of PDSS2 was evaluated using IHC.
Representative cases with reduced PDSS2 staining of GC
tissues are shown in Figure 2B. Overall, the staining pat-
terns of PDSS2 were consistent with the qRT-PCR data.Prognostic implications of PDSS2 mRNA expression levels
The expression of PDSS2 mRNA in GC tissues was
decreased in 76 (32%) of 238 patients (less than half the
level of expression detected in the corresponding normal
adjacent tissues). The disease-specific survival rate of
patients with decreased levels of PDSS2 mRNA in GCs
was significantly lower compared with those without
(5-year survival rates, 36% and 64%, respectively, P <0.001,
Figure 3A). Decreased levels of PDSS2 mRNA in GCs
were significantly associated with carbohydrate antigen
(CA) 19-9 > 37 IU/ml and lymph node metastasis (Table 1).
Univariate analysis of disease-specific survival showed
that GC subtype (proximal nondiffuse or diffuse), CA
19-9 > 37 IU/ml, tumor size (≥50 mm), pT4, undifferen-
tiated tumor, lymphatic involvement, vessel invasion,
invasive growth, lymph node metastasis, positive peritoneal
lavage cytology, and decreased PDSS2 mRNA expression in
GC tissues were significant prognostic factors of adverse
outcomes. Multivariate analysis identified decreased PDSS2
mRNA expression as an independent prognostic factor
(hazard ratio 1.95, 95% confidence interval 1.22–3.09,
P = 0.005, Table 2). The proportional hazards assumption
Figure 3 Prognostic implications of PDSS2 mRNA expression in patients with GC. (A) Disease-specific survival of patients with decreased
PDSS2 mRNA in GC tissue. (B) (C) Disease-specific (B) and recurrence-free (C) survival among 168 patients who underwent R0 resection.
Kanda et al. Journal of Experimental & Clinical Cancer Research 2014, 33:88 Page 5 of 8
http://www.jeccr.com/content/33/1/88in the Cox model was assessed with models including
time-by-covariate interactions and no significant violations
were found in the model.
Of the 168 patients who underwent R0 resection, the
disease-specific survival rate was significantly lower for
those with decreased PDSS2 mRNA expression in GCs
(n = 50) compared with those without (n = 118) (5-year
survival rates, 50% and 77%, respectively, P = 0.006,
Figure 3B). Patients with decreased PDSS2 mRNA
expression in GCs experienced significantly earlier
recurrences after surgery compared with those without
(2-year recurrence-free survival rates, 64% and 84%,
respectively, P = 0.022, Figure 3C). Initial recurrence sites
of 43 relapsing patients with decreased PDSS2 mRNA
expression in GCs were peritoneal in 21 (49%), liver in
6 (14%), lymph node in 13 (30%) and others (e.g. lung
and bone) in 3 patients. On the other hand, those of 61
relapsing patients without decreased PDSS2 were peri-
toneal in 35 (57%), liver in 10 (16%), lymph node in 8
(13%) and others in 8 patients. Patients with decreased
PDSS2 mRNA expression in GCs were likely to have a
node relapse, though it did not reach the statistical
significance.Subgroup analysis of PDSS2 expression according to
GC subtype
Mean PDSS2 mRNA expression levels were equivalent
in GC and normal adjacent tissues (Figure 4A). Simi-
larly, the prognostic value of decreased PDSS2 mRNA
expression in GCs was comparable among the three GC
subtypes (Figure 4B).Discussion
PDSSs are heterotetrameric enzymes comprising subunits
encoded by PDSS1 (10p12.1) and PDSS2 [10,12]. PDSS
activity requires both subunits [10,14,15]. The association
of PDSS2 with GC was considered because of its chromo-
somal location (6q21), and because of its inactivation or
loss from certain malignancies [16,26]. Here we show that
PDSS2 mRNA was heterogeneously expressed in GC cell
lines, and its expression was inhibited in 73% and 32% of
GC cell lines and tumor tissues, respectively. We detected
hypermethylation of the PDSS2 promoter in five (45%) of
11 GC cell lines with significantly decreased levels of
PDSS2 expression. Further, PDSS2 transcription was reac-
tivated after cells were treated with an inhibitor of DNA
methylation. These findings are the first to our knowledge
to show that promoter hypermethylation regulates PDSS2
transcription. However, PDSS2 expression was decreased in
some GC cells without hypermethylation. Because chromo-
some 6q is a frequent site of LOH in GC [17,26,27], LOH
may regulate PDSS2 expression as well.
There has been a report demonstrating that PDSS2 was
expressed at decreased or undetectable expression in a
small number of biopsy GC samples [18]. In the present
study, we analyzed 238 surgical specimens of tumors and
the corresponding uninvolved tissue to gain further insight
into the clinical significance of PDSS2 expression in GC.
Consistent with analyses of malignant melanoma and lung
cancer [11,12], most patients with GC harbored a decreased
level of PDSS2 mRNA in GC tissues, and the mean PDSS2
expression level was significantly decreased in GC com-
pared with normal adjacent tissues. IHC was conducted
to determine whether the mRNA level reflected PDSS2
Table 1 Association between expression level of PDSS2
mRNA and clinicopathological parameters of 238 patients
Variables Decreased PDSS2






< 65 year 29 71





Proximal nondiffuse 22 32
Diffuse 14 33




≤ 5 59 132




≤ 37 55 139
> 37 21 23
Tumor size (mm) 0.104
< 50 29 80
≥ 50 47 82














Infiltrative growth type 0.443
Invasive growth 24 59








Table 1 Association between expression level of PDSS2







Distant metastasis (UICC) 0.228
M0 50 119
M1 26 43
*Statistically significant (P <0.05). GC, gastric cancer; UICC, Union for
International Cancer Control.
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that the mRNA data were consistent with the protein
level, subsequent analyses were performed according to
the mRNA data, which are more amenable to the quan-
titative analysis [7,23].
Decreased PDSS2 mRNA expression in GCs was sig-
nificantly associated with elevated preoperative CA19-9
levels and lymph node metastasis and was identified as
an independent prognostic factor. Moreover, patients with
decreased PDSS2 mRNA expression in GC tissue experi-
enced significantly earlier recurrence after R0 resection.
Recently, Chen et al. investigated the tumor-suppressing
activity of PDSS2 in lung cancer [28]. They reported that
the forced overexpression of PDSS2 caused massive cell
death through apoptotic pathways and significantly inhib-
ited colony formation and there was an inverse correlation
between PDSS2 expression and gelsolin expression, which
is known to inhibit apoptosis and enhance cell invasion
and metastasis [29], though PDSS2 did not influence the
sensitivity of the cancer cells to chemotherapeutic drugs
[28]. This tumor suppressive mechanism of PDSS2 might
be applied to GC as well.
The expression pattern of PDSS2 mRNA and its prog-
nostic impact were similar among the three GC subtypes
(proximal nondiffuse, diffuse, and distal nondiffuse), indi-
cating that PDSS2 expression influences the pathogenesis
of all types of GC. Shah et al. reported that one-third
of amplified genes, possibly including PDSS2, showed
equivalent expression pattern among the three GC
subtypes [9].
GC is one of the tumors with a high frequency of
aberrant methylation, and it frequently exhibits the CpG
island methylator phenotype [30,31]. The expression of a
large number of genes is suppressed by CpG island
hypermethylation in GC cells, including those encoding
tumor suppressors, cell cycle regulators, inducers and
executioners of apoptosis, proteins that promote the
invasive phenotype, and DNA mismatch repair enzymes
[32]. These epigenetic alterations can serve as bio-
markers that illuminate an increased metastatic potential
Table 2 Prognostic factors for disease-specific survival of 238 patients
Variables n (%) Univariate Multivariable
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Age (≥65) 138 (58%) 1.04 0.67 – 1.61 0.843
Gender (female) 59 (25%) 1.29 0.79 – 2.05 0.301
Subtype (distal nondiffuse) 136 (57%) 0.43 0.28 – 0.67 <0.001 0.64 0.40 – 1.01 0.056
Carcinoembryonic antigen (>5 ng/ml) 47 (20%) 1.48 0.86 – 2.42 0.149
Carbohydrate antigen 19-9 (>37 IU/ml) 44 (18%) 1.98 1.17 – 3.20 0.012 1.23 0.71 – 2.06 0.445
Tumor size (≥50 mm) 129 (54%) 2.86 1.78 – 4.80 <0.001 1.40 0.83 – 2.42 0.211
Tumor depth (pT4, UICC) 110 (46%) 4.17 2.61 – 6.88 <0.001 1.38 0.78 – 2.50 0.273
Tumor differentiation (undifferentiated) 139 (58%) 2.03 1.28 – 3.32 0.002 1.45 0.83 – 2.60 0.197
Lymphatic involvement 203 (85%) 6.31 2.36 – 25.8 <0.001 1.45 0.45 – 6.50 0.559
Vessel invasion 134 (56%) 2.65 1.66 – 4.37 <0.001 1.75 1.07 – 2.97 0.026*
Invasive growth 83 (35%) 3.03 1.97 – 4.70 <0.001 1.19 0.70 – 2.05 0.520
Lymph node metastasis 149 (63%) 7.02 3.70 – 15.1 <0.001 1.38 0.56 – 3.81 0.503
Peritoneal lavage cytology (positive) 50 (21%) 4.33 2.76 – 6.74 <0.001 1.87 1.14 – 3.06 0.014*
UICC stage (III-IV) 140 (59%) 9.68 4.97 – 21.8 <0.001 2.63 0.94 – 7.83 0.065
Decreased PDSS2 mRNA in GCs 76 (32%) 2.18 1.40 – 3.37 <0.001 1.91 1.19 – 3.04 0.008*
*Statistically significant in multivariate analysis. GC, gastric cancer; CI, confidence interval; UICC, Union for International Cancer Control.
Figure 4 Subgroup analysis of GC subtypes. (A) PDSS2 mRNA
expression levels among the three GC subtypes both in GC and
normal adjacent tissues. (B) Comparison of disease-specific survival
of patients with and without decreased PDSS2 mRNA expression in
GCs of each GC subtype.
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peutic targets [34]. Therefore, identification of other
genes that are regulated by methylation in GC cells will
likely improve the management of GC.
The tumor suppressive function of PDSS2 are supported
by the present findings as follows: (1) decreased expression
of PDSS2 was frequently detected in GC tissues, (2) the
mean level of PDSS2 expression was significantly lower in
GC tissues, and (3) decreased expression of PDSS2 was
associated with early recurrence and subsequent poor prog-
nosis. PDSS2 expression levels in biopsy tissue obtained
using endoscopic surveillance samples or in surgical speci-
mens may be useful for predicting early recurrence and
poor prognosis, which will likely aid efforts to design more
efficacious therapeutic strategies.
This study was limited by its lack of sufficient func-
tional analysis of PDSS2, which tempers the conclusion
that it acts as a tumor suppressor in GC. Further studies
including pathway analysis in gastric carcinogenesis and
functional analysis are expected to clarify the molecular
mechanisms underlying the biological activities of PDSS2
in GC.
Conclusion
In conclusion, our findings support the conclusion that
the expression of the putative tumor suppressor gene
PDSS2 is regulated by promoter hypermethylation in GC
cells and indicate. Our results indicate further that
decreased expression of PDSS2 mRNA may represent a
novel biomarker for progression and recurrence of all
types of GC.
Kanda et al. Journal of Experimental & Clinical Cancer Research 2014, 33:88 Page 8 of 8
http://www.jeccr.com/content/33/1/88Additional file
Additional file 1: Table S1. Primers and annealing temperature.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MK, HO, FS, DS, HT, RH and KM performed experiments and data analysis.
DK, CT, SY, TF, GN, HS, MK, MF and YK collected cases and clinical data. MK
and SN conceived and designed the study, and prepared the initial
manuscript. YK supervised the project. All authors contributed to the final
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Naoki Iwata for his support to collect clinical data.
Author details
1Department of Gastroenterological Surgery (Surgery II), Nagoya University
Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
2Center for Advanced Medicine and Clinical Research, Nagoya University Hospital,
Nagoya, Japan.
Received: 27 July 2014 Accepted: 3 October 2014
References
1. Wang Z, Wang J, Yang Y, Hao B, Wang R, Li Y, Wu Q: Loss of has-miR-337-
3p expression is associated with lymph node metastasis of human
gastric cancer. J Exp Clin Cancer Res 2013, 32:76.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
3. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC,
Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ:
Screening for gastric cancer in Asia: current evidence and practice.
Lancet Oncol 2008, 9:279–287.
4. Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, Hashimoto R,
Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike
M, Fujiwara M, Kodera Y: Dihydropyrimidinase-like 3 facilitates malignant
behavior of gastric cancer. J Exp Clin Cancer Res 2014, 33:66.
5. Wang YY, Li L, Zhao ZS, Wang YX, Ye ZY, Tao HQ: L1 and epithelial cell
adhesion molecules associated with gastric cancer progression and
prognosis in examination of specimens from 601 patients. J Exp Clin
Cancer Res 2013, 32:66.
6. Resende C, Thiel A, Machado JC, Ristimaki A: Gastric cancer: basic aspects.
Helicobacter 2011, 16(Suppl 1):38–44.
7. Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, Hashimoto R,
Suenaga M, Inokawa Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama
G, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Prognostic impact of
expression and methylation status of DENN/MADD domain-containing
protein 2D in gastric cancer. Gastric Cancer 2014, Epub ahead of print,
PubMed PMID: 24695972.
8. Lauren P: The two histological main types of gastric carcinoma: diffuse
and so-called intestinal-type carcinoma. An attempt at a histo-clinical
classification. Acta Pathol Microbiol Scand 1965, 64:31–49.
9. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP:
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res
2011, 17:2693–2701.
10. Saiki R, Nagata A, Kainou T, Matsuda H, Kawamukai M: Characterization of
solanesyl and decaprenyl diphosphate synthases in mice and humans.
Febs j 2005, 272:5606–5622.
11. Chen P, Yu J, Knecht J, Chen Q: Decrease of PDSS2 expression, a novel
tumor suppressor, in non-small cell lung cancer. Cancer Epidemiol 2013,
37:166–171.
12. Fung JM, Smith R, Brown MA, Lau SH, Xie D, Lau GK, Guan XY:
Identification and characterization of a novel melanoma tumor
suppressor gene on human chromosome 6q21. Clin Cancer Res 2009,
15:797–803.
13. Quinzii CM, DiMauro S, Hirano M: Human coenzyme Q10 deficiency.
Neurochem Res 2007, 32:723–727.14. DiMauro S, Quinzii CM, Hirano M: Mutations in coenzyme Q10
biosynthetic genes. J Clin Invest 2007, 117:587–589.
15. Turunen M, Olsson J, Dallner G: Metabolism and function of coenzyme Q.
Biochim Biophys Acta 2004, 1660:171–199.
16. Li BC, Chan WY, Li CY, Chow C, Ng EK, Chung SC: Allelic loss of
chromosome 6q in gastric carcinoma. Diagn Mol Pathol 2003, 12:193–200.
17. Carvalho B, Seruca R, Carneiro F, Buys CH, Kok K: Substantial reduction of
the gastric carcinoma critical region at 6q16.3-q23.1. Genes Chromosomes
Cancer 1999, 26:29–34.
18. Chen P, Zhao SH, Chu YL, Xu K, Zhu L, Wu Y, Song J, Cao CX, Xue X, Niu YY:
Anticancer activity of PDSS2, prenyl diphosphate synthase, subunit 2, in
gastric cancer tissue and the SGC7901 cell line. Anticancer Drugs 2009,
20:141–148.
19. Sobin LH, Gospodarowicz MK, C W: International Union Against Cancer, TNM
Classification of Malignant Tumors. 7th edition. New York: Wiley-Blackwell; 2009.
20. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A,
Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y,
Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an
oral fluoropyrimidine. N Engl J Med 2007, 357:1810–1820.
21. Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M,
Yamada S, Inokawa Y, Nishikawa Y, Asai M, Fujii T, Sugimoto H, Kodera Y:
Downregulation of DENND2D by promoter hypermethylation is
associated with early recurrence of hepatocellular carcinoma. Int J Oncol
2014, 44:44–52.
22. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N,
Takeda S, Nakao A: Detection of metallothionein 1G as a methylated
tumor suppressor gene in human hepatocellular carcinoma using a
novel method of double combination array analysis. Int J Oncol 2009,
35:477–483.
23. Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, Kobayashi D,
Yamada S, Inokawa Y, Tanaka C, Fujii T, Sugimoto H, Koike M, Fujiwara M,
Kodera Y: Clinical significance of expression and epigenetic profiling of
TUSC1 in gastric cancer. J Surg Oncol 2014, 110:136–144.
24. Takai D, Jones PA: The CpG island searcher: a new WWW resource.
In Silico Biol 2003, 3:235–240.
25. Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y,
Sugimoto H, Takeda S, Nakao A: Promoter hypermethylation of fibulin 1
gene is associated with tumor progression in hepatocellular carcinoma.
Mol Carcinog 2011, 50:571–579.
26. Queimado L, Seruca R, Costa-Pereira A, Castedo S: Identification of two
distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosomes
Cancer 1995, 14:28–34.
27. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A: Comprehensive
allelotyping of human hepatocellular carcinoma. Oncogene 1997,
14:2927–2933.
28. Chen P, Zhang Y, Polireddy K, Chen Q: The tumor-suppressing activity of
the prenyl diphosphate synthase subunit 2 gene in lung cancer cells.
Anticancer Drugs 2014, 25:790–798.
29. An JH, Kim JW, Jang SM, Kim CH, Kang EJ, Choi KH: Gelsolin negatively
regulates the activity of tumor suppressor p53 through their physical
interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res
Commun 2011, 412:44–49.
30. Jang BG, Kim WH: Molecular pathology of gastric carcinoma. Pathobiology
2011, 78:302–310.
31. Kim TY, Jong HS, Jung Y, Kim TY, Kang GH, Bang YJ: DNA hypermethylation in
gastric cancer. Aliment Pharmacol Ther 2004, 20(Suppl 1):131–142.
32. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ:
Promoter hypermethylation of tumor-related genes in gastric intestinal
metaplasia of patients with and without gastric cancer. Int J Cancer 2002,
102:623–628.
33. Janjigian YY, Kelsen DP: Genomic dysregulation in gastric tumors. J Surg
Oncol 2013, 107:237–242.
34. Bird A: Perceptions of epigenetics. Nature 2007, 447:396–398.
doi:10.1186/s13046-014-0088-3
Cite this article as: Kanda et al.: Decreased expression of prenyl
diphosphate synthase subunit 2 correlates with reduced survival of
patients with gastric cancer. Journal of Experimental & Clinical Cancer
Research 2014 33:88.
